AZ Joins Spin-Out Set, Forms GI Play Albireo

AstraZeneca has completed its first ever biotech spin out, creating the Swedish biotech firm Albireo with backing led by Nomura Phase4 Ventures. The deal underscores pharma's disenchantment with certain aspects of GI drug development and may blaze a trail for other non-core areas of R&D at the drugmaker.

In mid February, AstraZeneca PLC completed its first ever biotech spin-out, backed by $27 million from Nomura Phase4 Ventures, TVM Capital, and Scottish Widows Investment Partnership, in the first close of a round that could reach $40 million. [See Deal] The formation of Albireo AB, a Gothenburg-based gastrointestinal play with a clinical-stage chronic constipation candidate and a small handful of undisclosed preclinical compounds, charts new territory for the Big Pharma and suggests a practical outlook when it comes to assets that have been sidelined as part of a strategic review—even if the company is in no hurry to repeat the process immediately.

Albireo begins life focused on ALBI 3309, an orally available novel-mechanism molecule first tested in chronic constipation; AstraZeneca had previously...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.